Clinical significances of p27 in digestive tract cancers: a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data
Metrics: PDF 434 views | HTML 855 views | ?
Dan-Dan Xiong1,*, Rong-Quan He2,*, Ai-Hua Lan1, Wen-Jie Chen1, Yi-Huan Luo1, Zhi-Hua Ye1, Jie Ma2, Gang Chen1 and Yi-Wu Dang1
1Department of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region 530021, China
2Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region 530021, China
*These authors contributed equally to this work
Yi-Wu Dang, email: email@example.com
Keywords: digestive tract cancers; p27; immunohistochemistry; prognoses; clinical significances
Received: March 20, 2017 Accepted: December 05, 2017 Published: January 23, 2018
In the present study, we conducted a comprehensive analysis on the clinical roles of p27 protein and p27 gene in digestive tract cancers (DTCs). First, we performed immunohistochemistry staining and found that p27 protein was down-regulated in DTCs. Then we collected 62 publications and calculated the combined hazard ratios (HRs), odds ratios (ORs) and 95% confidence intervals (95% CIs) to clarify the relationships of p27 protein expression with prognoses and clinicopathological parameters. The overall HRs indicated that the down-regulated p27 protein was an independent prognostic biomarker for overall survival (HR: 1.58, 95% CI: 1.38–1.81, P < 0.0001) but not for disease–free survival and cancer–specific survival. The combined ORs indicated that a low expression of p27 protein was positively related to lymph node metastasis (OR: 2.15, 95% CI: 1.57–2.96, P < 0.0001), distant metastasis (OR: 2.02, 95% CI: 1.12–3.63, P = 0.019) and pathology grading (OR: 2.14, 95% CI: 1.75–2.62, P < 0.0001). Additionally, 60 DTCs-related microarray and RNA-seq datasets were obtained to investigate the expression level and clinical value of p27 gene in DTCs patients. We found that the expression level of p27 gene in DTCs was similar to that in normal controls. And no significant associations of p27 gene expression with prognoses and clinicopathological factors were observed. In conclusion, according to our results, it was p27 protein, but not p27 gene, that can function as an effective biomarker to predict the clinical outcome in patients with DTCs. The down-regulation of p27 protein in DTCs may not result from the altered expression of p27 gene.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.